Compare AJG & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AJG | BDX |
|---|---|---|
| Founded | 1927 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.1B | 55.1B |
| IPO Year | N/A | 1962 |
| Metric | AJG | BDX |
|---|---|---|
| Price | $257.73 | $197.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $293.69 | $213.13 |
| AVG Volume (30 Days) | 1.7M | ★ 2.2M |
| Earning Date | 01-29-2026 | 02-04-2026 |
| Dividend Yield | 1.03% | ★ 2.15% |
| EPS Growth | ★ 20.23 | N/A |
| EPS | ★ 6.33 | 5.82 |
| Revenue | $12,078,600,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $28.42 | $4.00 |
| Revenue Next Year | $24.54 | $3.40 |
| P/E Ratio | $40.03 | ★ $33.61 |
| Revenue Growth | ★ 13.23 | 8.24 |
| 52 Week Low | $236.34 | $162.29 |
| 52 Week High | $351.23 | $251.99 |
| Indicator | AJG | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 58.15 | 56.69 |
| Support Level | $249.13 | $194.09 |
| Resistance Level | $257.37 | $202.75 |
| Average True Range (ATR) | 5.02 | 3.72 |
| MACD | 2.34 | -0.14 |
| Stochastic Oscillator | 99.38 | 60.19 |
Founded in 1927 as a one-person agency, Gallagher's primary business is insurance brokerage, with a focus on serving middle-market companies. The company's risk management segment provides third-party claims adjustment to companies that choose to self-insure. Gallagher has about 56,000 employees and generates about a third of its revenue internationally, primarily in Australia, Canada, New Zealand, and the UK.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.